![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » LAB INTERNATIONAL SECURES $2.22 MILLION FOR DRUG DEVELOPMENT FROM NATIONAL TECHNOLOGY AGENCY OF FINLAND
LAB INTERNATIONAL SECURES $2.22 MILLION FOR DRUG DEVELOPMENT FROM NATIONAL TECHNOLOGY AGENCY OF FINLAND
October 21, 2005
LAB International Inc. (TSX: LAB, Frankfurt: LD9.F, XETRA: LD9.DE) ("LAB"), an integrated drug development company with subsidiaries focused on developing therapies for the inhalation market and on providing contract research services, today announced that LAB Pharma, it's drug development subsidiary headquartered in Finland, has secured approximately $2.22 million (1.55 million euros) to support product development.
PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-20-2005/0004173807&EDATE=)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
21Oct